Hepatitis D virus (HDV) is a tiny, defective pathogen that can only infect people who are also infected with hepatitis B virus (HBV). It borrows the outer coat of HBV to get into liver cells, making it the only known human virus that is completely dependent on another virus to spread and cause disease. Despite that parasitic limitation, HDV causes the most severe form of viral hepatitis, accelerating liver damage well beyond what hepatitis B does alone. Understanding this unusual virus matters because it affects millions of people worldwide, has had almost no treatment options for decades, and sits in a genuinely strange corner of biology that challenges how we think about what a virus even is.
A Virus That Cannot Work Alone
HDV needs HBV’s surface protein, called HBsAg, to wrap itself in an envelope and enter liver cells. Without that envelope, HDV particles cannot attach to the receptor on hepatocytes that lets them inside. This is not a loose partnership; HDV is structurally incapable of completing its life cycle without borrowing HBV’s coat proteins.1PubMed Central. Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus Once inside the cell, however, HDV replicates its own genome independently using the host cell’s own machinery. It does not need HBV’s help for that step, only for packaging and leaving.
This dependency means you cannot catch HDV unless you are already carrying HBV or pick up both viruses at the same time. In practice, that creates two distinct infection patterns. A coinfection happens when someone is exposed to both HBV and HDV simultaneously, often through contaminated blood or shared needles. In most coinfection cases, the immune system clears both viruses, and the person recovers. A superinfection is different and far more dangerous: someone who already has chronic hepatitis B later encounters HDV. In that scenario, the vast majority of patients develop chronic HDV infection, which piles additional liver damage on top of the ongoing hepatitis B.2PubMed Central. Hepatitis D virus coinfection and superinfection
The Smallest and Strangest Human Virus Genome
HDV’s genome is a single strand of circular RNA, roughly 1,700 nucleotides long. That makes it the smallest genome of any known animal virus. The RNA folds back on itself to form a rigid, rod-like structure, a feature that gives it an uncanny resemblance to viroids, which are circular RNA pathogens that infect plants.3PubMed. The molecular biology of hepatitis delta virus Viroids are even smaller than HDV and have no protein-coding genes at all, so the comparison highlights just how minimal HDV really is. The virus codes for only one protein, called the delta antigen, which comes in two forms and is essential for replication.4Seminars in Virology. Organization and Expression of the Hepatitis Delta Virus Genome
One of HDV’s most remarkable features is its built-in ribozyme, a stretch of RNA that can cut and rejoin itself without any protein assistance. This self-cleaving ability is central to the way HDV copies itself through a process called rolling-circle replication, where the host cell’s own RNA polymerases produce long chains of repeated copies that the ribozyme then snips into individual genome-length pieces.5PubMed Central. Rolling circle replication of hepatitis delta virus RNA is carried out by two different cellular RNA polymerases These structural and functional similarities to viroids have led some researchers to describe HDV as a possible “molecular fossil” of the RNA world, the hypothesized era before DNA and proteins dominated biology.6PubMed. Viroids and hepatitis delta virus Whether or not HDV truly descends from that primordial era, its stripped-down genome and self-splicing RNA stand out as biological curiosities with few parallels in the animal kingdom.
How Much Liver Damage Does HDV Cause
Chronic HDV infection is the most aggressive form of viral hepatitis. Compared with hepatitis B alone, the addition of HDV leads to faster progression toward cirrhosis and liver failure.7PubMed Central. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? The immune response to HDV appears to play a role in this accelerated damage, though the precise mechanisms that drive disease progression remain poorly understood.8PubMed Central. Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy
The cancer risk is also elevated. A meta-analysis pooling data from 21 studies found that people with both HBV and HDV had roughly double the odds of developing liver cancer compared with those who had HBV alone.9PubMed Central. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis That is a meaningful jump in risk on top of an already dangerous infection, and it underscores why identifying HDV-positive patients early matters for monitoring and treatment decisions.
Who Gets HDV and Where
Global estimates of how many people carry HDV vary depending on methodology, but the numbers are large. One systematic review estimated that about 12 million people worldwide test positive for HDV antibodies, corresponding to roughly 4.5% of all HBsAg-positive individuals. Prevalence was highest in Mongolia, Moldova, and countries in western and middle Africa, and was particularly elevated among people who inject drugs, recipients of hemodialysis, and men who have sex with men.10PubMed Central. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis A separate analysis using a broader methodology put the number even higher, estimating about 48 to 60 million infections globally, with Asia and Africa bearing the greatest burden.11The Journal of Infectious Diseases. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection
The discrepancy between those two estimates reflects different assumptions about testing coverage and which populations were included. Many countries simply do not routinely screen HBV carriers for HDV, so the true burden is almost certainly higher than reported. A more recent country-by-country adjusted analysis found that Mongolia had the highest prevalence among HBV-positive individuals at over 60%, while China had the highest absolute number of people with active HDV replication, driven by its enormous HBV-positive population.12PubMed. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories In high-income countries, HDV is less common in the general population but clusters among immigrant communities from endemic regions and among people who inject drugs.
Diagnosis and Why It Is Often Missed
Diagnosing HDV requires a two-step process. The first step is an antibody test (anti-HDV), which shows whether someone has ever been exposed to the virus. If that test comes back positive, the second step is an HDV RNA test, which determines whether the virus is actively replicating. The RNA test is the one that confirms current infection and guides treatment decisions. Studies evaluating HDV RNA assays found them to be highly accurate, with sensitivity around 92% and specificity around 90%.13PubMed Central. Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis
The practical problem is that many clinicians never order the first test. In many health-care systems, there is no automatic reflex to screen HBV-positive patients for HDV. The result is widespread underdiagnosis. Someone living with chronic hepatitis B might go years without being tested for HDV, during which time their liver disease is progressing faster than their doctor expects. Major hepatology guidelines now recommend that all HBsAg-positive patients be tested for HDV antibodies at least once, but implementation remains patchy.
Treatment Options Old and New
For decades, pegylated interferon-alpha was the only treatment that showed any benefit against chronic HDV, and it remains the first-line option recommended by the European Association for the Study of the Liver for patients with compensated liver disease.14Exploration of Digestive Diseases. Pharmacotherapy of hepatitis D: the current and the future The results, though, are far from satisfying. Across studies, only about a quarter to a third of patients achieve sustained suppression of HDV replication after a standard course of 48 weeks.15PubMed. Interferon-based treatment of chronic hepatitis D The side effects are substantial, including flu-like symptoms, fatigue, depression, and blood-count abnormalities, and the drug cannot be used in patients whose liver disease has already advanced to decompensated cirrhosis.16PubMed Central. Updates on Recent Advancements in Hepatitis D Virus Treatment
The picture has begun to change with bulevirtide, a drug that blocks HDV’s entry into liver cells by occupying the receptor HDV uses to get inside.17PubMed. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D Bulevirtide was approved in Europe in 2020, making it the first drug specifically licensed for chronic HDV. It is administered as a daily subcutaneous injection and appears to suppress HDV RNA levels in a meaningful proportion of patients, though questions about how long treatment needs to continue and whether it can fully clear the virus remain open.
Another drug further back in the pipeline is lonafarnib, which works through an entirely different mechanism. HDV’s larger form of the delta antigen needs a chemical modification called prenylation to interact with HBV’s surface proteins and assemble new viral particles. Lonafarnib blocks that modification.18PubMed Central. Recent breakthroughs in the treatment of chronic hepatitis Delta In an early-phase trial, patients receiving the higher dose showed a meaningful drop in circulating HDV RNA over 28 days of treatment.19PubMed Central. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial Lonafarnib has the advantage of being an oral pill rather than an injection, but gastrointestinal side effects have been a challenge in trials, and it is still being evaluated in later-stage studies.
Why There Is No HDV Vaccine but You Can Still Prevent It
There is no vaccine that targets HDV directly. But because HDV is absolutely dependent on HBV, the hepatitis B vaccine indirectly prevents hepatitis D as well. If your immune system can block HBV, HDV has no way in. The hepatitis B vaccine is, in this sense, the only current method of preventing HDV infection.20PubMed Central. Hepatitis B Vaccine: Four Decades on
Modeling studies show that achieving high HBV vaccination coverage, at or above 80% in newborns, could eventually drive both HBV and HDV toward elimination, though the timeline is long because the existing pool of chronically infected adults would not benefit from infant vaccination programs.21PLOS ONE. The Impact of Vaccination and Antiviral Therapy on Hepatitis B and Hepatitis D Epidemiology Any faster reduction in HDV requires additional measures, including screening and treatment of chronic HBV carriers and vaccination of at-risk adults who missed childhood immunization. For someone already living with chronic hepatitis B, the HBV vaccine offers no protection against HDV superinfection, which is why treatment and monitoring strategies matter so much for that group.
Not All HDV Is the Same
Eight distinct genotypes of HDV have been identified. Genotype 1 is the most common worldwide and dominates in Europe, North America, the Middle East, and parts of Asia. Other genotypes cluster in specific regions: genotype 5, for instance, is found primarily in West Africa. These genotypic differences are not just academic. A study comparing genotypes 1 and 5 found that patients with genotype 5 developed cirrhosis and liver failure less often and responded significantly better to interferon treatment, with post-treatment response rates of 64% for genotype 5 compared with 10% for genotype 1.22PubMed. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1 Genotyping is not yet part of routine clinical practice for HDV, but findings like these suggest it probably should be, especially as new therapies become available and clinicians need to tailor expectations.
What Liver Transplantation Looks Like for HDV Patients
When chronic HDV infection progresses to end-stage liver disease, transplantation becomes the remaining option. The good news is that outcomes after liver transplant for HDV patients are generally favorable, partly because HDV recurrence can be prevented by blocking HBV from re-establishing itself in the new liver. Hepatitis B immunoglobulin, often combined with antiviral drugs, is given after transplant to keep HBsAg from reappearing. Without that surface protein, HDV cannot infect the graft. In one large single-center study, HDV recurrence occurred in fewer than 7% of transplanted patients over a median follow-up of nearly seven years, and immunoglobulin administration was strongly protective.23PubMed Central. Long-Term Post-transplant Outcomes in Patients with Hepatitis D Virus Infection at a High-Volume Liver Transplant Center
An open question is whether lifelong immunoglobulin is strictly necessary or whether it can eventually be stopped. The limited data available suggest that discontinuation may be safe, but no randomized controlled trial has confirmed this.24PubMed. Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins? For now, most transplant centers continue immunoglobulin prophylaxis indefinitely, erring on the side of caution given HDV’s severity.
Mother-to-Child Transmission
HDV does not appear to have its own independent route of vertical transmission from mother to infant. The risk of a baby acquiring HDV at birth is tied entirely to whether perinatal HBV transmission occurs. If the baby does not pick up HBV, HDV has no foothold.25PubMed. Perinatal transmission of the hepatitis B virus and of the HBV-associated delta agent from mothers to offspring in northern Italy This reinforces the importance of the standard protocol for babies born to HBV-positive mothers: hepatitis B vaccine and immunoglobulin administered within hours of birth. When that protocol is followed, the odds of perinatal HBV infection drop sharply, and HDV infection is prevented along with it.
HDV-Like Viruses in the Animal Kingdom
For most of its history, HDV was considered a uniquely human problem, inseparable from human HBV. That assumption began to unravel in 2018 and the years that followed, when researchers mining RNA sequencing databases found HDV-like agents in a startling range of animals. Deltavirus-related sequences have now been identified in birds (zebra finches, canaries, Gouldian finches), mammals (woodchucks, white-tailed deer), amphibians (toads, newts), fish, and even termites.26PubMed Central. Identification of novel avian and mammalian deltaviruses provides new insights into deltavirus evolution27Virus Evolution. Novel hepatitis D-like agents in vertebrates and invertebrates
The truly surprising part is that none of these animal deltaviruses were found alongside a hepadnavirus like HBV. That challenges the longstanding assumption that deltaviruses are permanently tethered to hepatitis B-like helpers.28PubMed Central. HDV-Like Viruses Whatever envelope these animal deltaviruses use to get around, it is not coming from a hepadnavirus. This raises the possibility that human HDV’s relationship with HBV may be a relatively recent evolutionary acquisition rather than a fundamental feature of deltavirus biology. It also suggests that the deltavirus lineage is far older and more widespread than anyone suspected, potentially stretching back hundreds of millions of years across the animal tree of life.